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Abstract
Purpose Posterior fossa brain tumours (PFT) and their treatment in young children are often associated with subsequent 
cognitive impairment. However, reported follow-up periods rarely exceed 10 years. This study reports very long-term cogni-
tive consequences of surviving an early childhood PFT.
Methods 62 adult survivors of a PFT, ascertained from a national register, diagnosed before 5 years of age, and a sibling 
control, received a single IQ assessment an average of 32 years (range 18–53) after initial diagnosis, using the Weschler 
Abbreviated Scale of Intelligence. Regression models were fitted to survivor–sibling pair differences on verbal and perfor-
mance IQ (VIQ and PIQ) scores to investigate whether increasing time between PFT diagnosis and follow-up IQ assessment 
contributed to survivor–sibling IQ differences.
Results At follow-up, survivors had, on average, VIQ 15 points and PIQ 19 points lower than their siblings. There was no 
significant effect of time since diagnosis on survivor–sibling VIQ difference. Survivors who received radiotherapy showed 
no significant effect of time since diagnosis on survivor–sibling PIQ difference. Survivors who did not receive radiotherapy 
demonstrated a trend for it to reduce.
Conclusions VIQ and PIQ deficits persist in adulthood, suggesting the effect of a fixed injury imposing on cognitive devel-
opment, rather than an ongoing pathological process.
Implications for cancer survivors The findings will help parents and others supporting survivors of an early life PFT to 
identify and plan for possible cognitive outcomes, and highlight the importance of early interventions to optimize cognitive 
function during the developmental period.
Keywords Posterior fossa · Childhood brain tumour · Survivorship · Cognition
Introduction
Posterior fossa brain tumours (PFT) and their treatment in 
children can be associated with subsequent cognitive impair-
ment [1–4]. Rates of survival from childhood brain tumours 
have been increasing but tumour management tends to be 
more challenging in younger children and it is amongst 
these survivors that greater cognitive morbidity is observed 
[5–9]. Factors associated with increased risk of later cogni-
tive decline include, most powerfully, radiotherapy [10–13].
Longer periods since diagnosis are associated with more 
impaired intellectual functioning [7, 9, 10, 14, 15]. However, 
whilst many studies have described short- and medium-term 
cognitive outcomes in survivors of a childhood PFT (see 
reviews by Robinson et al. [3], de Ruiter et al. [10], Nathan 
et al. [16]), few have investigated long-term cognitive out-
comes in later adulthood of PFT survivors diagnosed in early 
childhood [3, 6, 9, 11].
This study reports long-term cognitive consequences of 
surviving an early childhood PFT. The results should be 
relevant for survivors, their families and their clinicians, 
and for services supporting adults with a history of an early 
childhood PFT.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1014 7-020-01725 -7) contains 
supplementary material, which is available to authorized users.
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Methods
Study design
Adult survivors of a childhood PFT, diagnosed before the 
age of 5 years, were identified from the UK National Regis-
try of Childhood Tumours (UK NRCT), which holds clinical 
data going back as far as the 1940s. We aimed to recruit a 
complete as possible sample across England to participate 
in a single face-to-face assessment including an established 
IQ measure. To provide an approximate indication of how 
pre-morbid intellectual ability may have developed in these 
survivors if they had not had a brain tumour, we measured 
the IQ of a non-affected sibling of each survivor. This work 
was part of a wider project that examined mental health out-
comes in adult survivors of early childhood PFT [17].
Eligibility criteria
Adults aged at least 18 years at follow-up who had been 
diagnosed with a PFT before the age of 5 years, between the 
years 1940 and 1991, were identified from the UK NRCT 
and recruited through their General Practitioners (GPs). In 
the main analyses reported here, the adult survivor group 
comprised all those for whom a sibling provided comparison 
IQ data (Fig. 1). Siblings were recruited through the index 
participants, with one sibling recruited for each index par-
ticipant. Where more than one sibling was available, the one 
closest in age to the index participant was recruited.
Approvals and consent
Approval was given by the Cambridgeshire 2 Research Eth-
ics Committee and UK National Information Governance 
Board. Informed consent was obtained from all individual 
participants included in the study who had capacity to con-
sent. Participants lacking capacity were included where 
agreement was gained from family or carers, as required by 
the Mental Capacity Act (England and Wales) 2005.
Assessments
IQ was measured using the Wechsler Abbreviated Scale of 
Intelligence (WASI) [18]. This is a standardised, psycho-
metrically robust, brief measure of intelligence assessing 
verbal knowledge, verbal reasoning, visual information 
processing, and visual perception, through the use of four 
subtests: vocabulary and similarities to measure verbal IQ 
(VIQ), block design and matrix reasoning to measure perfor-
mance IQ (PIQ) [18]. The WASI correlates highly with the 
equivalent full Wechsler Adult Intelligence Scale (WAIS-III, 
[19]; WASI and WAIS-III correlations [18]: VIQ 0.88, PIQ 
0.84), but makes fewer demands on participants.
A structured psychiatric assessment was also undertaken, 
results from which have been published previously [17].
Tumour registry data
For each survivor, age at diagnosis, sex, tumour type and 
treatment received were extracted from the NRCT. Avail-
able treatment details varied between participants, so cra-
nial radiotherapy, chemotherapy and surgery descriptions 
were dichotimised to confirmed use, or not, of the treatment. 
Tumour types were condensed into astrocytoma, medullo-
blastoma or ‘other’.
Statistical analysis
The main aim is to investigate whether increasing time 
since tumour diagnosis affects VIQ and PIQ outcomes in 
adulthood of survivors of an early childhood PFT. We also 
investigate if the changes over time differ for those who had 
received radiotherapy.
Univariate group comparisons tested differences between 
groups of survivors and their siblings using Fisher’s exact 
test and t tests as appropriate. Subsequently, within the sur-
vivors, we investigated relationships between VIQ and PIQ, 
cancer treatment received, age at diagnosis and sex, using 
Fig. 1  Flow chart of recruitment. Adapted from Carroll et al. [17]
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Fisher’s exact test and t-tests as appropriate. Finally, regres-
sion models further investigated differences in IQ between 
survivors and their siblings.
Odds ratios (ORs) and Pearson’s correlation coefficient 
(r) are used as measures of effect size. In places, Pearson’s 
r was calculated from t-statistics, as described in Field et al. 
[20], using a formula from Rosenthal and Rubin [21]. Effect 
sizes are interpreted according to the benchmarks in Cohen 
[22].
Statistical analysis: regression modelling
The difference between survivors’ and their siblings’ VIQ 
and PIQ scores was analysed using generalised additive 
models (GAMs); these were fitted using the mgcv package 
(see Wood [23]) in the statistical software R.
In each model, the sibling’s IQ score is included as a 
covariate to act as a proxy for unmeasured confounders 
(elements of environment, including shared family environ-
ment and genetics). We also include a quadratic form of the 
IQ measures as a further covariate in case the relationship 
with unmeasured confounders is not linear. Both linear and 
quadratic forms of the sibling measures are centered (using 
a mean of 100).
Further covariates (levels of categorical variables denoted 
in parentheses) include: survivor sex; sibling sex (same, dif-
ferent); epilepsy (present, absent); (centred) time in years 
since diagnosis; age in months at diagnosis; tumour type 
(astrocytoma, medulloblastoma, other); radiotherapy (no 
confirmed treatment, confirmed radiotherapy); surgery (no 
confirmed surgery, confirmed surgery). GAMs allow fitting 
of a penalized regression spline to time since diagnosis, the 
covariate of primary interest, allowing more flexible rela-
tionships (rather than a straight line); Supplementary mate-
rials present an analysis restricted to linear relationships for 
comparison.
We consider five interactions (denoted ‘ × ’): survivor 
sex × sibling sex; survivor sex × radiotherapy (explores how 
the IQ of female survivors is affected by radiotherapy); 
radiotherapy × surgery; tumour type × radiotherapy; and time 
since diagnosis × radiotherapy (explores how the effect of 
radiotherapy differs over time, within GAM framework this 
results in separate curves for each level of radiotherapy). 
Within each set of GAMs, models were compared using the 
second-order Akaike Information Criterion (AICc [24, 25], 
a small sample size version of the standard AIC), where 
lower values indicate a better fitting model, to investigate 
the importance of the five interactions.
Results
Recruitment
A potential maximum of 396 survivors were initially iden-
tified from the UK NRCT. Of these, 213 people could be 
contacted via their GP and 118 took part, representing a 
55% response amongst contactable survivors (Fig. 1). A 
non-responder analysis demonstrated that demographic 
and cancer characteristics were similar between these 118 
participants and those not participating (see Supplementary 
Materials in Carroll et al. [17]). Of the 118 participant sur-
vivors, 62 with a sibling who provided comparison data are 
reported on here. There was no indication of selection bias 
comparing suvivors without a recruited sibling (see Sup-
plementary material).
Survivors: demographics and other characteristics
Mean age at data collection was similar across females (35.6) 
and males (34.2) (t(52) = − 0.545, p = 0.588; r = 0.075) as 
was years of education in excess of 10 years for females (3.1) 
and males (3.2) (t(42) = 0.190, p = 0.850; r = 0.029). Twelve 
survivors had epilepsy and epilepsy history was unknown 
for one individual.
Survivors: diagnosis and treatment details
Details of survivors’ age at diagnosis, tumour, and treatment 
are in Table 1. There was little difference in the age at which 
males (39.6 months) and females (42.0) had been diagnosed 
(t(51) = − 0.714; p = 0.478; r = 0.100). Tumour type did not 
affect age of diagnosis (F(2,59) = 0.979, p = 0.382). There 
was no difference between sexes in the proportion that 
received surgery (Fisher’s exact test: p = 1.000; OR = 1.127). 
For further analysis of variables associated with surgery, see 
Supplementary Materials.
Astrocytoma was the most common tumour type (n = 40) 
and included: fibrillary—3; pilocytic—28; NOS—9. All the 
medulloblastoma (n = 15) were recorded as ‘medulloblas-
toma, NOS’. The ‘Other’ group of tumours included: tumour 
cells—1; subependymoma—1; ‘ependymoma, NOS’—4; 
‘spongioblastoma, NOS’—1.
Age at diagnosis was not associated with whether radio-
therapy was received (t(47) = − 0.314; p = 0.755; r = 0.045). 
While not statistically significant (t(49) = − 1.513; 
p = 0.137), those who received radiotherapy had been diag-
nosed further into the past than those who had not (mean 
time since diagnosis (years): received radiotherapy = 32.9, 
no radiotherapy = 29.0), with a small to medium effect 
(r = 0.212). There was little difference between sexes in the 
proportion who received radiotherapy (Fisher’s exact test: 
1766 International Journal of Clinical Oncology (2020) 25:1763–1773
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p = 0.429; OR = 0.589). Radiotherapy was more common for 
medulloblastomas (radiotherapy: medulloblastoma = 87%, 
astrocytomas = 48%, other = 57%; Fisher’s exact test: 
p = 0.025). Five survivors received chemotherapy in addition 
to radiotherapy. No participant had chemotherapy without 
radiotherapy.
There was no significant difference in the proportion 
having surgery between those treated without radiotherapy 
(88%) and with radiotherapy (78%) (Fisher’s exact test: 
p = 0.332; small to medium effect,OR = 2.16). Around 45% 
(28/62) of survivors had radiotherapy and surgery.
Demographic comparisons between survivors 
and siblings
Descriptions of the 62 tumour survivors and their sibling 
comparators are given in Table 2.
IQ comparisons between survivors and siblings
Table 2 provides the VIQ and PIQ summary scores. The sur-
vivors’ VIQ scores were significantly lower on average than 
their siblings, by a mean difference of 15 points (p < 0.001; 
r = 0.655), and their PIQ scores by a mean difference of 19 
points (p < 0.001; r = 0.670). However, these mean group 
differences, as displayed in Supplementary Figure  S1, 
include a wide range of differences in IQ scores between 
survivors and siblings.
Supplementary Table 1 provides the IQ sub-test scores for 
survivors and siblings, demonstrating similar magnitudes of 
difference between sibling and survivor across all subtests. 
Unadjusted group IQ scores separated by sex are detailed in 
Supplementary Table S2.
Mean VIQ and PIQ for different tumour types, along with 
sibling comparison IQ scores, are reported in Supplementary 
Table 3. For survivors, means of VIQ and PIQ by tumour 
type are similar. When compared with their siblings, those 
with medulloblastomas score worse on VIQ (mean differ-
ence compared to siblings: medulloblastomas = − 20.7, 
astrocytomas = − 13.5 and ‘other’ tumour type = − 14.7); 
however, this variation in difference is small (r ≈ 0.7 versus 
r ≈ 0.6).
GAM: verbal IQ
The VIQ GAM with lowest AICc is reported in Table 3 and 
includes two interactions (survivor sex × sibling sex; survi-
vor sex × radiotherapy). In this model n = 61 (one participant 
has missing information about epilepsy), adjusted R2 = 0.32 
and diagnostic plots suggest no problems with model fit.
A plot of the smooth showing the effect of time since 
diagnosis on VIQ difference is shown in Fig. 2 (top): there 
is no significant evidence (p = 0.5330) that this relationship 
differs from a horizontal line at zero (shown in the figure by 
the confidence region around the smooth being centred on 
the red line, plotted at zero difference). The fitted smooth has 
estimated degrees of freedom (EDF) of 1.8, approaching a 
Table 1  Survivor diagnosis and 
treatment information
SD standard deviation
Diagnosis/treatment attribute Statistics/N
Age at diagnosis Months Mean = 40.5, 
median = 44.0, 
SD = 13.3, 
range = 4–59
Time since diagnosis Years Mean = 31.3, 
median = 29.5, 
SD = 9.9, 
range = 18–53
Tumour type Astrocytoma 40
Medulloblastoma 15
Other 7
Radiotherapy
Chemotherapy
No confirmed treatment 26
Confirmed radiotherapy 31
Confirmed radiotherapy and chemotherapy 5
Surgery No recorded surgery 11
Biopsy only 1
Palliative surgery 2
Removal (unspecified type) of primary tumour 8
Partial removal of primary tumour 18
Total removal of primary tumour 22
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quadratic relationship [matching the gentle ‘u’ shape seen in 
the Fig. 2 (top)]. This model does not include an interaction 
between the smooth (i.e. time since diagnosis) and radiother-
apy: this suggests little evidence for an effect of radiotherapy 
on VIQ difference changing over time (otherwise a model 
including this interaction would have had a lower AICc and 
subsequently been selected).
Male survivors who had radiotherapy have VIQ scores 
that are on average 2.7 points closer to their siblings’ VIQ 
scores than male survivors who did not have radiotherapy 
(b = 2.7; 95% CI − 8.5, 13.8; p = 0.641). However, there is 
strong evidence (p = 0.013) that in female survivors, radio-
therapy increases the VIQ difference between them and their 
siblings by around 19 points (− 22 + 2.7 ≈ 19; b = − 22.0; 
95% CI − 38.7, − 5.2).
This analysis is repeated in the Supplementary Materi-
als in a linear modelling framework, where the relationship 
between time since diagnosis and VIQ difference is restric-
tricted to a straight line. The model fits are very similar to 
those here and subsequent conclusions the same.
The Supplementary Materials also include a GAM as 
above, but extended to include two new covariates for addi-
tional years beyond compulsory education for survivors and 
siblings, respectively. Due to missing data on these covari-
ates, the sample size reduces to n = 48. Conclusions are simi-
lar to the above primary analysis (time since diagnosis has 
no significant impact on VIQ; radiotherapy has a significant 
and larger impact on females).
GAM: performance IQ (PIQ)
The PIQ GAM with lowest AICc is reported in Table 3 
and includes one interaction (time since diagnosis × radio-
therapy). In this model n = 60 (one participant has missing 
information about epilepsy and another is missing PIQ), 
adjusted R2 = 0.41 and diagnostic plots suggest no problems 
with model fit.
As there is an interaction between time since diagno-
sis and radiotherapy, a separate time since diagnosis rela-
tionship is estimated for those not receiving/receiving 
radiotherapy.
Figure 2 (middle) shows the estimated effect of time since 
diagnosis on PIQ on the n = 25 people who did not receive 
radiotherapy. A linear relationship (EDF = 1) is estimated, 
in which the PIQ difference increases (gets better) as time 
since diagnosis increases. This relationship approaches sig-
nificance (p = 0.0822): the confidence interval region on 
Fig. 2 (middle) only just encompasses the line (red) of no 
difference.
Figure 2 (bottom) shows the estimated effect of time since 
diagnosis on PIQ on the n = 35 people who did receive radi-
otherapy. A linear relationship (EDF = 1) is estimated, in 
which the PIQ difference gets worse slightly as time since 
Table 2  Differences between the 62 survivor and sibling pairings
Paired t tests are used for comparing continuous variables between groups. One survivor could not complete PIQ subtests due to vision prob-
lems, and so has no corresponding PIQ score
a N = 56
b N = 59
c N = 50
d N = 61
Attribute Survivors Siblings Survivor v. sibling (unadjusted) comparisons
Mean SD Range Mean SD Range
Sex: females n = 24 – – n = 36 – – Fisher’s exact test, p = 0.048, OR = 0.459
Employed n = 39a – – n = 48b – – Fisher’s exact test, p = 0.196, OR = 1.890
Age (months) at data collection 34.8 10.1 19–57 35.0 10.8 19–59 t(61) = − 0.502, Dif = − 0.3 (95% CI − 1.4, 0.8), p = 0.617, 
r = 0.064
Age (years; deciles)
 19–29 n = 26 – – n = 23 – – Fisher’s exact test, p = 0.714
 30–39 n = 16 – – n = 19 – –
 40–49 n = 15 – – n = 12 – –
 50–59 n = 5 – – n = 8 – –
Years beyond compulsory education 3.2c 2.2 0–7 4.3b 2.5 0–7 t(47) = − 3.013, Dif = − 1.3 (95% CI − 2.1, − 0.4), 
p = 0.004, r = 0.402
Verbal IQ 88.3 18.1 55–121 103.7 12.0 77–127 t(61) = − 6.774, Dif = − 15.4 (95% CI − 19.9, − 10.8), 
p < 0.001, r = 0.655
Performance IQ 91.1d 20.3 55–129 110.0 12.3 83–134 t(60) = − 6.982, Dif = − 19.1 (95% CI − 24.6, − 13.7), 
p < 0.001, r = 0.670
1768 International Journal of Clinical Oncology (2020) 25:1763–1773
1 3
Ta
bl
e 
3 
 Th
e fi
t o
f t
he
 ge
ne
ra
lis
ed
 ad
di
tiv
e m
od
els
 (G
AM
s) 
re
lat
in
g v
er
ba
l I
Q 
(V
IQ
) a
nd
 pe
rfo
rm
an
ce
 IQ
 (P
IQ
) d
iff
er
en
ce
 (s
ur
vi
vo
r I
Q-
sib
lin
g I
Q)
 to
 th
e c
ov
ar
iat
es
Th
e “
Si
bl
in
g 
(c
or
re
sp
on
di
ng
) I
Q”
 is
 si
bl
in
g 
VI
Q 
in
 th
e V
IQ
 m
od
el 
an
d 
sib
lin
g 
PI
Q 
in
 th
e P
IQ
 m
od
el.
 C
ell
s o
nl
y 
co
nt
ain
in
g 
hy
ph
en
s i
nd
ica
te 
ter
m
s n
ot
 in
clu
de
d 
in
 a 
m
od
el.
 B
ol
d 
ita
lic
s i
nd
ica
te 
a p
 va
lu
e <
0.0
5. 
Fi
ts 
of
 th
e s
m
oo
th
s o
f t
im
e s
in
ce
 di
ag
no
sis
 in
clu
de
d i
n t
he
 m
od
els
 ar
e s
ho
wn
 in
 F
ig
. 2
a  ‘M
ed
ul
lo
bl
as
to
m
a’ 
tak
en
 as
 re
fer
en
ce
 le
ve
l
b ‘N
o c
on
fir
m
ed
 tr
ea
tm
en
t’ 
tak
en
 as
 re
fer
en
ce
 le
ve
l
c ‘A
bs
en
t’ 
tak
en
 as
 re
fer
en
ce
 le
ve
l
d ‘ N
o r
ec
or
de
d s
ur
ge
ry
’ t
ak
en
 as
 re
fer
en
ce
 le
ve
l
e ‘ M
en
’ u
se
d a
s r
efe
re
nc
e l
ev
el
f ‘ S
am
e a
s s
ur
vi
vo
r’ 
tak
en
 as
 re
fer
en
ce
 le
ve
l
Va
ria
bl
e
Ca
teg
or
ica
l l
ev
el
VI
Q 
(n
 =
 61
; a
dj
us
ted
 R
2  =
 0.
32
)
PI
Q 
(n
 =
 60
; a
dj
us
ted
 R
2  =
 0.
41
)
b
95
% 
CI
p v
alu
e
r
b
95
% 
CI
p v
alu
e
r
In
ter
ce
pt
–
− 
18
.9
− 
40
.2
2.5
0.0
90
0.2
47
0.0
− 
23
.8
23
.7
0.9
97
0.0
00
Ag
e a
t d
iag
no
sis
 (m
on
th
s)
–
− 
0.2
− 
0.5
0.2
0.3
79
0.1
30
0.3
0.0
0.7
0.0
74
0.2
58
Tu
m
ou
r  t
yp
ea
As
tro
cy
to
m
a
4.2
− 
6.3
14
.8
0.4
37
0.1
15
− 
3.0
− 
14
.9
8.8
0.6
20
0.0
73
Ot
he
r
9.8
− 
4.9
24
.5
0.1
99
0.1
88
− 
5.0
− 
22
.1
12
.2
0.5
72
0.0
83
Ra
di
ot
he
ra
py
b
Co
nfi
rm
ed
 ra
di
ot
he
ra
py
2.7
− 
8.5
13
.8
0.6
41
0.0
69
− 
18
.0
− 
27
.7
− 
8.3
<0
.00
1
0.4
68
Ep
ile
ps
yc
Pr
es
en
t
− 
7.4
− 
17
.6
2.8
0.1
60
0.2
05
− 
9.5
− 
21
.2
2.2
0.1
17
0.2
27
Su
rg
er
yd
Co
nfi
rm
ed
 su
rg
er
y
15
.4
3.8
27
.0
0.
01
3
0.3
57
4.3
− 
7.8
16
.3
0.4
91
0.1
01
Su
rv
ivo
r  s
ex
e
Fe
m
ale
− 
2.6
− 
16
.1
11
.0
0.7
11
0.0
55
− 
16
.8
− 
26
.0
− 
7.5
<0
.00
1
0.4
61
Si
bl
in
g  s
ex
f
Di
ffe
re
nt
 to
 su
rv
ivo
r
− 
7.5
− 
17
.9
2.8
0.1
61
0.2
05
− 
4.1
− 
13
.5
5.3
0.3
95
0.1
24
Si
bl
in
g (
co
rre
sp
on
di
ng
) I
Q 
(c
en
tre
d)
–
− 
0.2
− 
0.6
0.2
0.3
68
0.1
33
− 
0.6
− 
1.2
0.1
0.0
78
0.2
54
Si
bl
in
g (
co
rre
sp
on
di
ng
)  I
Q2
 (c
en
tre
d)
–
0.0
0.0
0.0
0.9
72
0.0
05
0.0
0.0
0.0
0.0
71
0.2
60
Su
rv
ivo
r ×
 si
bl
in
g s
ex
Fe
m
ale
:si
b s
ex
 di
ff.
 in
ter
18
.8
0.7
37
.0
0.
04
7
0.2
87
–
–
–
–
–
Su
rv
ivo
r s
ex
 ×
 ra
di
ot
he
ra
py
Fe
m
ale
:th
er
ap
y i
nt
er
ac
tio
n
− 
22
.0
− 
38
.7
− 
5.2
0.
01
3
0.3
53
–
–
–
–
–
1769International Journal of Clinical Oncology (2020) 25:1763–1773 
1 3
diagnosis increases. This relationship is not significant 
(p = 0.5235): the confidence interval region on Fig. 2 (bot-
tom) is just off-centre of the line (red) of no difference.
Radiotherapy is associated, on average, with a significant 
(p < 0.001) and sizeable (r = 0.468) decrease (worsening) of 
18 (b = − 18.0; 95% CI − 27.7, − 8.3) PIQ points (given the 
model parameterisation, this corresponds to the radiother-
apy difference at approximately 31 years after diagnosis, 
the mean time since diagnosis). There is little evidence of 
this differing by sex, as the model does not include survivor 
sex × radiotherapy (otherwise a model including this interac-
tion would have had a lower AICc).
This analysis is repeated in the Supplementary Materials 
in a linear modelling framework. As the estimated smooths 
are straight lines, the GAM and linear model are very simi-
lar, with the same conclusions.
The Supplementary Materials also include a GAM as 
above, but extended to include two new covariates for addi-
tional years beyond compulsory education for survivors and 
siblings respectively. Due to missing data on these covari-
ates, the sample size reduces to n = 48. In contrast to the 
primary analysis above, there is no interaction between time 
since diagnosis and whether survivors receive radiotherapy. 
This difference is driven by two aspects of this secondary 
analysis which limit its wider applicability: first, the reduced 
sample size leads to a loss of statistical power to detect 
interactions; and second, there is a differential missing-
ness on additional years beyond compulsory education and 
radiotherapy treatment—12% (3/26) among survivors not 
receiving radiotherapy, and 31% (11/36) among survivors 
who received radiotherapy. The differential missingness may 
induce a selection bias that we cannot quantify, and the loss 
of statistical power induces a model that averages across the 
two groups rather than producing group-specific estimates. 
As in the primary analysis above, radiotherapy significantly 
impacts on PIQ, but there is no evidence of a differential 
effect by sex.
Fig. 2  GAM smooth estimates 
for the relationship between 
time since diagnosis (years), 
while adjusting for all other 
covariates in the model in 
Table 3, and a verbal IQ (VIQ); 
b performance IQ (PIQ) among 
those with no confirmed radio-
therapy; c PIQ among those 
with confirmed radiotherapy. 
The PIQ model includes an 
interaction between the smooth 
and radiotherapy, hence we 
have two smooths for PIQ b 
and c. The y-axis represents the 
difference between survivors’ 
and their siblings’ IQ scores; 
however, the difference shown 
must be combined with the 
effect of other covariates from 
Table 3 to be interpreted. Since 
survivor’s scores are, on aver-
age, lower than their siblings 
the difference in scores will be 
negative (survivor minus sibling 
will be less than zero); hence, a 
positive smooth value indicates 
the difference is decreased (ie 
survivors IQs are improving by 
getting closer to that of their 
siblings). Each panel includes a 
rug plot, showing the contribut-
ing participants/observations
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Discussion
This study investigated, in adult survivors of an early child-
hood PFT, effects on intellectual functioning of increasing 
time since tumour diagnosis. No previous studies of long-
term neurocognitive outcomes of childhood PFT survivors 
have focused on the question investigated here: namely, is 
increasing time since diagnosis, continuing well into adult-
hood, associated with later changes in IQ. Intellectual func-
tioning was assessed using the WASI index measures of VIQ 
and PIQ. In the absence of repeated IQ measures within indi-
viduals across time, in this study, VIQ and PIQ were meas-
ured on a single occasion in a cohort of survivors between 18 
and 53 years after their tumour was diagnosed. Siblings’ IQ 
provided an estimated proxy for what individual survivors’ 
IQ might have been had they not developed tumours.
Results indicated that, compared to their siblings, older 
adult survivors of a childhood PFT did not have relatively 
lower VIQ and PIQ scores than younger adult survivors. 
However, relative IQ deficits did persist in adulthood, with 
the possible exception of PIQ scores in survivors who did 
not receive radiotherapy, in whom there was a trend towards 
a reduction in survivor–sibling PIQ difference with greater 
time since PFT diagnosis. Our results were broadly robust to 
the inclusion of covariates that measure educational levels 
(see Results—no improving trend for PIQ was found for 
survivors who did not receive radiotherapy, but this is likely 
driven by greater levels of missing data in the secondary 
analysis). Our data do not allow any conclusions to be drawn 
regarding the possible basis for differences between VIQ and 
PIQ over time. It may be relevant that in a recent study of 
children treated below the age of 4 years for a medulloblas-
toma, whose cognitive performance was assessed an aver-
age of 4.9 years after their surgery, it was noted that those 
who had received cranial–spinal irradiation were particu-
larly impaired on motor decision time [26]. Further research 
will be needed to establish the time course of the effect of 
radiotherapy on this aspect of cognitive performance and to 
address the question of whether it relates to long-term dif-
ferences between PIQ and VIQ outcomes.
Our findings indicating that following a childhood PFT 
relative cognitive deficits tend to persist is in line with other 
studies that have undertaken long-term follow-up in this 
clinical group. Schreiber et al. [27] noted that in male chil-
dren followed for 5 years after surgery for a medulloblas-
toma, those whose acute treatment had been associated with 
the development of posterior fossa syndrome had relatively 
more impaired cognitive performance at one year post-
surgery than those who did not develop it. Many of those 
impairments were still present 4 years later, and in some 
cases, declined further over the 4 years of follow-up. They 
concluded that early brain insult associated with posterior 
fossa syndrome may contribute to an acute decline in atten-
tion, processing speed, and working memory with very little 
recovery over time. They also concluded, given that most of 
their participants received low-dose radiation, that posterior 
fossa syndrome was a greater predictor of neurocognitive 
impairment than low-dose radiation. Posterior fossa syn-
drome is reported in up to 29% of those receiving surgery for 
medulloblastoma [28]. Whilst we do not have a figure for the 
prevalence of posterior fossa syndrome in the participants 
of the current study, it is likely to only have been present in 
a small proportion. Hence, whilst, like Schreiber et al. [27], 
we observed evidence suggesting the persistence across time 
of a range of cognitive deficits, in the population reported 
in the current study, it is unlikely that the explanation for 
this finding was the presence of a post-operative posterior 
fossa syndrome.
Considering findings from long-term follow-up studies, 
in one of the few previous studies that have followed survi-
vors treated for a PFT in childhood into adulthood, Reimers 
et al. [13] reported IQ in participants with a mean age of 
21.7 years and a mean age at diagnosis of 8.3 years. They 
observed a significant correlation between full-scale IQ and 
age at diagnosis but not between full-scale IQ and age at fol-
low-up. These findings suggests, in results compatible with 
those from the current study, that IQ does not change pro-
gressively with increasing time since diagnosis. However, 
the inferences to be drawn from their study are limited by 
the wider age range at diagnosis of their participants and the 
much shorter period of follow-up into adulthood. Ellenberg 
et al. [11] examined adult cognitive outcomes in survivors 
of a childhood CNS malignancy. They observed a range of 
neurocognitive symptoms in adulthood, using a self-reported 
behavioural rating inventory, and did not examine potential 
effects of increasing intervals of time between original diag-
nosis and follow-up in adulthood.
Our results also showed that, regardless of time elapsed 
since tumour diagnosis, a history of receiving radiotherapy 
was associated with relatively greater lowering of VIQ 
scores in female survivors and greater lowering of PIQ 
scores in both male and female survivors. Including covari-
ates for educational level led to the same conclusions. The 
association between a history of childhood radiotherapy and 
subsequent cognitive impairment has been much researched 
and reduced white matter integrity has been proposed as 
contributing to persisting deficits in neurocognitive function. 
This may particularly be the case given the role of white mat-
ter in cortical information processing and integration [29]. 
Links with damage to various white matter tracts have been 
reported [30, 31]. It has also been demonstrated recently that 
in addition to long-term effects of radiotherapy on cognition, 
functional impairments in cognition and diffuse white matter 
changes may be detected as soon as 3 months after treatment 
with wider-field, cranial–spinal radiotherapy compared to 
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local radiotherapy [32]. Those authors also noted, however, 
that their group who had received just surgery, or surgery 
with local radiotherapy did over a subsequent follow-up 
period of 3 years also experience cognitive decline, although 
of lesser magnitude than those who had received cranial-
spinal radiotherapy.
In a study that investigated white matter tract integrity 
in young adults a mean of 13 years after their brain tumour 
diagnosis, King et al. [31] reported an association between a 
history of radiotherapy, lower IQ at follow-up and disrupted 
white matter tract integrity. As noted by King et al. [31], the 
white matter disruption they detected could have reflected 
loss of white matter, delayed maturation of white matter, 
or individual vulnerability to neurotoxicity associated with 
the tumour or its management. The results of the present 
study, with data indicating a persisting detrimental effect of 
radiotherapy on IQ across participants who were assessed an 
average of 32.9 years after diagnosis, a considerably longer 
follow-up period than that reported by King et al. [31], sug-
gests that of the possibilities proposed by King et al. [31], 
delayed maturation appears to be unlikely.
The reasons for the sex differences in the pattern of IQ 
results in those who received radiotherapy are unclear. 
Whilst no sex differences in intellectual outcomes have been 
reported in some studies [7], other reports do suggest that 
females may be more likely to have more adverse neuro-
cognitive outcomes [33]. Ellenberg et al. [11], in a study of 
children and young people aged from 0–20 years when diag-
nosed with a central nervous system malignancy, reported 
that female sex predicted more impaired scores on two meas-
ures of self-reported neurocognitive outcome; Task Effi-
ciency and Emotional Regulation scales, with small effect 
sizes. Ris et al. [15] on the other hand, in a study of children 
and young people aged 3–21 years with a medulloblastoma 
treated with radiotherapy and chemotherapy, found no effect 
of sex on intellectual outcome measured using WISC or 
WAIS IQ tests between 2 and 5 years after tumour diagnosis. 
Possible reasons for these differences in observed effects of 
sex on intellectual outcome may include treatments prevail-
ing during the eras in which the participants were treated 
and the length of follow-up. The participants reported by 
Ris and colleagues were all treated after 1996, whilst those 
reported in the current study were treated between 1940 and 
1991. Given the efforts to reduce radiation doses that have 
been pursued over time, it is possible that those reported 
here had received larger and less focused doses at a young 
age. However, the higher average age of tumour diagnosis 
and shorter follow-up period reported by Ris et al. [15] may 
also underpin the absence of observations of greater female 
vulnerability to adverse effects on IQ. Our finding of greater 
cognitive impairment in female survivors following a period 
of follow-up of at least 18 years, is congruent with the obser-
vation by Hudson et al. [34], in survivors of a wide range 
of cancers, that female survivors had a greater and steeper 
trajectory of decline in at least one health domain compared 
to their same sex sibling than did male survivors. It has also 
been noted that female survivors of acute lymphoblastic 
leukaemia are at increased risk for neurocognitive impair-
ment, whether they received radiotherapy or chemotherapy 
[16]. There is also evidence that in non-cancer brain injury 
females may have worse outcomes that males [35, 36]. No 
specific mechanism underlying poorer cognitive outcomes in 
females after brain insult have been identified, though with 
respect to post-menarche females sustaining traumatic brain 
injury, it has been proposed that disrupted physiology of 
gonadal steroids, possibly through an effect on the anterior 
pituitary gland, may play a role [36].
In line with the North American Childhood Cancer sur-
vivor study, we chose to recruit a sibling comparison group, 
controlling for shared genetic and sociodemographic factors 
[37]. Previous research has demonstrated that the degree 
of hereditability for general intellectual functioning (g) is 
estimated as around 50% [38].
There are several limitations to our study. It is not longi-
tudinal: instead of following survivors over time to examine 
changes in intellectual functioning, a cross-sectional design 
was used in which participants had a single IQ assessment. 
This design is limited by the age–period–cohort problem 
[39] and cannot separate effects of age-group, periods and 
cohorts; so cannot determine whether IQ changes relate 
to survivor age or to changes in treatment practices from 
1940 to 1991. Additionally, our primary analysis does not 
include covariates that measure educational level—a quan-
tity known to correlate with IQ—due to levels of missing 
data. However, we have conducted secondary analysis to 
check how our conclusions are impacted by variables that 
measure educational level: results are comparable given the 
reduced sample size.
Importantly, any study of treatment effects after follow-up 
periods of several decades will face the issue that treatment 
practices will have changed since the interventions were car-
ried out. This does not invalidate the findings of the present 
study. First, this study provides information relevant to cur-
rent adult survivors of an early childhood PFT, their families 
and clinicians, as to what may be expected with regard to 
cognitive performance during adulthood. Second, the cur-
rent study provides a base for future follow-up studies of 
later cohorts of long-term survivors from clinical trials run 
during the 1990s and 2000s and who are now in their 20s 
and 30s, and comparison of our findings with data from such 
future studies would address the question of whether or not 
the observed pattern of long-term outcomes remain similar 
despite all the changes in treatment practices.
Our cognitive data are limited to estimates of VIQ and 
PIQ, meaning we cannot draw conclusions regarding specific 
aspects of cognition that would be of interest, for instance, 
1772 International Journal of Clinical Oncology (2020) 25:1763–1773
1 3
processing speed. However, it is important to note that alter-
native opportunities for follow-up over as long as 50 years 
are limited.
Our observation that VIQ deficits, and PIQ deficits in 
those receiving radiotherapy, develop during childhood but 
persist, without further decline, in adulthood, suggests that 
the effects on intellectual functioning take the form of a fixed 
injury that imposes itself on subsequent cognitive develop-
ment, rather than an ongoing pathological process. This 
emphasises the importance of seeking early interventions 
to optimize cognitive function during the developmental 
period [40].
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